A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression

The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Giotopoulos, George, van der Weyden, Louise, Osaki, Hikari, Rust, Alistair G., Gallipoli, Paolo, Meduri, Eshwar, Horton, Sarah J., Chan, Wai-In, Foster, Donna, Prinjha, Rab K., Pimanda, John E., Tenen, Daniel G., Vassiliou, George S., Koschmieder, Steffen, Adams, David J., Huntly, Brian J.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577832/
https://www.ncbi.nlm.nih.gov/pubmed/26304963
http://dx.doi.org/10.1084/jem.20141661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577832/
https://www.ncbi.nlm.nih.gov/pubmed/26304963
http://dx.doi.org/10.1084/jem.20141661

Ejemplares similares